Tube Investments of India (TII) set up a manufacturing facility in Andhra Pradesh and a research and development (R&D) centre in Chennai. The efforts are part of the Murugappa Group company’s strategy to enhance its medical division’s contract development and manufacturing operations (CDMO). The company aims to capitalize on opportunities in the active pharmaceutical ingredients (API) sector within the pharmaceutical industry.
In 2023, TII introduced 3xper Innoventure, a new venture focused on the CDMO of APIs. The initiative aims to offer comprehensive chemistry solutions, encompassing discovery, development, and manufacturing services for global pharmaceutical, healthcare, and specialty chemical companies.
To support its expansion, the R&D facility in Chennai, is equipped with dedicated synthetic and analytical laboratories, emphasizing scale-up and technology transfer. As reported by projectstoday.com, a new plant is being constructed in Naidupeta, approximately 120 km from Chennai, for manufacturing purposes.
The facility is expected to be completed within the current financial year and will offer services ranging from small-scale material generation to commercial-scale manufacturing. To build capabilities and capacities, the Kilo lab has been commissioned, and the pilot plant is currently under construction.
